{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:17:17Z","timestamp":1790705837899,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/jcp.0b013e31829abec9","type":"journal-article","created":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T10:55:38Z","timestamp":1376736938000},"page":"593-599","source":"Crossref","is-referenced-by-count":41,"title":["The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol"],"prefix":"10.1097","volume":"33","author":[{"given":"Maja","family":"Zivkovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Mihaljevi\u0107-Peles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Bozina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sagud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matea","family":"Nikolac-Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjanka","family":"Vuksan-Cusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorotea","family":"Muck-Seler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rational, for consensus.","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R2-2-20210128","first-page":"114","article-title":"The concepts of remission and recovery in schizophrenia.","volume":"24","author":"Emsley","year":"2011","journal-title":"Curr Opin Psychiatry"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eurpsy.2010.12.011","article-title":"Peuskens JEuropean Group on Functional Outcomes, Remission in Schizophrenia. Setting new standards in schizophrenia outcomes: symptomatic remission 3 years before versus after the Andreasen criteria.","volume":"27","author":"Gorwood","year":"2012","journal-title":"Eur Psychiatry"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0193-953X(18)30166-7","article-title":"Neuroleptic-induce acute extrapyramidal syndromes and tardive dyskinesia.","volume":"16","author":"Casey","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine (D(2)) occupancy, clinical response and side effects, a double-blind PET study of first-episode schizophrenia.","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.psychres.2007.08.002","article-title":"Polymorphism of dopamine D2 receptor (TaqIB, TaqIB, and -141C InsDel) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.","volume":"161","author":"Lafuente","year":"2008","journal-title":"Psychiatry Research"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatment of schizophrenia; a critical review of pharmacology and mechanism of action of antipsychotic drugs.","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/070674379804300608","article-title":"Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.","volume":"43","author":"Lewis","year":"1998","journal-title":"Can J Psychiatry"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1517\/14656566.9.9.1451","article-title":"Antipsychotic-induced extrapyramidal symptoms and their management.","volume":"9","author":"Dayalu","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptors occupancy in patients treated with classical neuroleptics and clozapine. Relations to extrapyramidal side effects.","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R11-2-20210128","first-page":"15","article-title":"D2 and 5HT2 receptor effects of antipsychotic; bridging basic and clinical findings using PET.","volume":"60","author":"Remington","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","article-title":"Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.","volume":"7","author":"Zhang","year":"2011","journal-title":"Expert Opin Metab Toxicol"},{"key":"R13-2-20210128","first-page":"335","article-title":"Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.","volume":"22","author":"Mihaljevic-Peles","year":"2010","journal-title":"Psychiatr Danub"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.mp.4000350","article-title":"The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in health volunteers.","volume":"3","author":"Pohjalainen","year":"1998","journal-title":"Mol Psychiatry"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.mp.4000532","article-title":"Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.","volume":"4","author":"Jonsson","year":"1999","journal-title":"Mol Psychiatry"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.mp.4002023","article-title":"Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.","volume":"12","author":"Zai","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.mp.4002142","article-title":"Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetics interactions.","volume":"13","author":"Bakker","year":"2008","journal-title":"Mol Psychiatry"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/1096-8628(20000612)96:3<422::AID-AJMG35>3.0.CO;2-5","article-title":"No relationship between TaqIA polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective D2 antagonists, bromperidol and nemonapride in schizophrenia: a preliminary study.","volume":"96","author":"Mihara","year":"2000","journal-title":"Am J Med Genet"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.mp.4001054","article-title":"Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphism in patients with schizophrenia.","volume":"7","author":"Kaiser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00213-006-0622-x","article-title":"Serotonin and dopamine receptor gene polymorphisms and risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.","volume":"190","author":"Gunes","year":"2007","journal-title":"Psychopharmacology"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","article-title":"Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.","volume":"63","author":"Guzey","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/syn.20927","article-title":"Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.","volume":"65","author":"Costa","year":"2011","journal-title":"Synapse"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1600-0447.2002.1o174.x","article-title":"Dopamine transporter gene (DAT1) VNTR polymorphism in major psychiatric disorders: family-based association study in the Bulgarian population.","volume":"105","author":"Georgieva","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.mp.4000701","article-title":"Human dopamine transporter gene: coding region conservation among normal, Tourrettes disorder, alcohol dependence and attention-deficit hyperactivity disorder population.","volume":"5","author":"Vandenberg","year":"2000","journal-title":"Mol Psychiatry"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2006.09.031","article-title":"Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.","volume":"90","author":"Lafuente","year":"2007","journal-title":"Schizophr Res"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.psychres.2009.07.006","article-title":"Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport gene.","volume":"175","author":"Gasso","year":"2010","journal-title":"Psychiatry Res"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.pnpbp.2010.05.017","article-title":"Pharmacogenetics effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and extrapyramidal syndrome in schizophrenia.","volume":"34","author":"Xu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"key":"R30-2-20210128","first-page":"21","article-title":"Positive and negative symptom scale (PANNS) for schizophrenia.","volume":"13","author":"Kay","year":"1998","journal-title":"Schizophr Bull"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extra-pyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatry Scand"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells.","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acid Res"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/2.12.2197-a","article-title":"PCR detection of the TaqA RFLP at the DRD2 locus.","volume":"2","author":"Grandy","year":"1993","journal-title":"Hum Mol Genet"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00041444-200112000-00002","article-title":"Genetic polymorphisms of the promoter region of dopamine D2 receptor and dopamine transporter genes and alcoholism among four aboriginal groups and Han Chinese in Taiwan.","volume":"11","author":"Chen","year":"2001","journal-title":"Psychiatr Genet"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0888-7543(05)80138-7","article-title":"Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR.","volume":"14","author":"Vandenberg","year":"1992","journal-title":"Genomics"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0022-510X(03)00002-9","article-title":"The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinsons disease for male, but not to female patients.","volume":"209","author":"Lin","year":"2003","journal-title":"J Neurol Sci"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00213-010-2079-1","article-title":"Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.","volume":"214","author":"Kasten","year":"2011","journal-title":"Psychopharmacology"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management.","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Saf"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.","volume":"30","author":"Kane","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2004.09.020","article-title":"Meta-analysis shows schizophrenia is not associated with the 40-base pair repeat polymorphism of the dopamine transporter gene.","volume":"731","author":"Gamma","year":"2005","journal-title":"Schizophr Res"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0888-7543(03)00142-3","article-title":"Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene.","volume":"82","author":"Greenwood","year":"2003","journal-title":"Genomics"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2156-6-3","article-title":"Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1).","volume":"6","author":"Mill","year":"2005","journal-title":"BMC Genet"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.mp.4000921","article-title":"Polymorphisms in the 3-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression.","volume":"7","author":"Miller","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/sj.tpj.6500026","article-title":"The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression.","volume":"1","author":"Fuke","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1523\/JNEUROSCI.20-10-03864.2000","article-title":"Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons.","volume":"20","author":"Carr","year":"2000","journal-title":"J Neuroscience"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1126\/science.1066969","article-title":"A paradigm shift in brain research.","volume":"294","author":"Carlsson","year":"2001","journal-title":"Science"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(94)91117-7","article-title":"Haloperidol-induced morphological changes in striatum are associated with glutamate synapses.","volume":"648","author":"Meshul","year":"1994","journal-title":"Brain Res"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/mgme.2000.3015","article-title":"Molecular heterosis: a review.","volume":"71","author":"Comings","year":"2000","journal-title":"Mol Genet Metab"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.mp.4000343","article-title":"D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene.","volume":"3","author":"Laruelle","year":"1998","journal-title":"Mol Psychiatry"},{"key":"R50-2-20210128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.mp.4001054","article-title":"Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia.","volume":"7","author":"Kaiser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R51-2-20210128","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1440-1681.2008.04918.x","article-title":"Cyp2d63, 4, 5 and 6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.","volume":"35","author":"Crescenti","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s002280000222","article-title":"CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenia patients.","volume":"56","author":"Scordo","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/004982597240802","article-title":"Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization.","volume":"27","author":"Gilham","year":"1997","journal-title":"Xenobiotica"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31829abec9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:02:01Z","timestamp":1620957721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201310000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31829abec9","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}